A Study of LY3305677 in Participants With Obesity Or Overweight

Summary

The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.

Timeline

Start

2022-11-16

Primary completion

2023-06-27

Completion

2023-06-27

Publications

• Bhattachar SN, Tham LS, Li Y, Chua L, Ng SX, Tang Y, Ibriga H, Ni W, Gurbuz S, Mather KJ, Thomas MK. Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial. Diabetes Obes Metab. 2025 Nov;27(11):6460-6469. doi: 10.1111/dom.70040. Epub 2025 Aug 20.

Drugs

Indications